This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
by Zacks Equity Research
Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.
CANFNegative Net Change USNAPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know
by Zacks Equity Research
Amarin shares surge 37.7% in a year as restructuring, cost cuts and expanding Vazkepa partnerships for international growth fuel optimism.
AMRNNegative Net Change ANIPNegative Net Change
biotechs
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised)
by Zacks Equity Research
Acadia plans re-examination after CHMP rejects Rett syndrome drug trofinetide in the EU, delays potential approval despite positive LAVENDER study results.
USNAPositive Net Change ACADPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales
by Zacks Equity Research
BAYRY posts in-line Q4 earnings but revenues miss on lower Xarelto and Eylea sales. 2026 sales guidance signals steady growth ahead.
REGNPositive Net Change JNJPositive Net Change BAYRYNo Net Change
biotechnology biotechs earnings medical pharmaceuticals
TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study
by Zacks Equity Research
Theravance Biopharma shares plummet 26% after its phase III CYPRESS study of ampreloxetine missed key endpoints, prompting the company to halt the program.
VRTSPositive Net Change ANIPNegative Net Change TBPHNo Net Change
biotechs
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS
by Zacks Equity Research
Moderna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ending global litigation.
MRNANegative Net Change ABUSNegative Net Change ROIVNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU
by Zacks Equity Research
Acadia plans re-examination after CHMP rejects Rett syndrome drug trofinetide in the EU, delays potential approval despite positive LAVENDER study results.
USNAPositive Net Change ACADPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
by Zacks Equity Research
NVS wins CHMP backing for remibrutinib in chronic spontaneous urticaria, bringing its oral BTK inhibitor closer to EU approval.
REGNPositive Net Change SNYNegative Net Change NVSNegative Net Change
biotechs
Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan
by Zacks Equity Research
SNY wins Japan orphan drug tag for Waylirz in IgG4-RD and adds regulatory perks as the BTK inhibitor advances in late-stage studies.
SNYNegative Net Change AMGNPositive Net Change RIGLNegative Net Change
biotechs medical pharmaceuticals vaccines
Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
by Zacks Equity Research
RHHBY's fenebrutinib slashes RMS relapses by 51% in phase III, advancing its bid for a first high-efficacy oral therapy in MS.
REGNPositive Net Change NVSNegative Net Change RHHBYPositive Net Change
biotechnology biotechs medical pharmaceuticals